证券代码：301257 证券简称：普蕊斯 公告编号：2025-046 普蕊斯（上海）医药科技开发股份有限公司 关于参与竞拍和立置业部分股权及相应债权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、交易概述 为满足普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）经营 和未来发展需要、提高运营效率并优化公司资产结构，解决目前办公场所紧张且 通过租赁方式使用办公场所的不稳定性，进一步提升对优秀人才的吸引力，公司 于 2025 年 7 月 4 日召开第三届董事会第十三次会议及第三届监事会第十三次会 议，并于 2025 年 7 月 21 日召开 2025 年第二次临时股东大会，审议通过了《关 于参与竞拍和立置业部分股权及相应债权的议案》，同意公司通过以现金方式竞 买上海外滩投资开发（集团）有限公司（以下简称"外滩投资"）在上海联合产权 交易所（以下简称"联交所"）挂牌转让其持有的上海和立置业有限公司（以下简 称"和立置业"）45%股权（以下简称"标的股权"）及其对和立置业 5,836.17 万元 债权（以下简称"相应债权"）的形式，以实现购置办 ...

Group 1 - The stock price of Puris closed at 41.06 yuan on August 5, down 1.08% from the previous trading day [1] - The trading volume on that day was 20,774 hands, with a transaction amount of 0.85 billion yuan [1] - The company's total market capitalization is 3.244 billion yuan, and the circulating market capitalization is 3.093 billion yuan [1] Group 2 - Puris specializes in pharmaceutical research and development outsourcing services, focusing on providing clinical trial technical services for pharmaceutical companies [1] - The company is registered in Shanghai and is involved in various fields, including innovative drug development [1] Group 3 - On August 5, the net outflow of main funds was 8.5093 million yuan, with a cumulative net outflow of 70.8291 million yuan over the past five trading days [1] - The current stock price is at a critical position in technical indicators, and market trading shows a shrinking trend [1]

Group 1 - The latest stock price of the company, Puris, is 41.51 yuan, an increase of 0.73 yuan from the previous trading day's closing price [1] - The opening price on the same day was 40.60 yuan, with a high of 41.70 yuan and a low of 39.62 yuan, and the trading volume reached 28,453 hands with a transaction amount of 116 million yuan [1] - As of July 31, 2025, the number of shareholders decreased to 8,735, a reduction of 713 shareholders or 7.55%, marking the third consecutive reporting period of decline, totaling a decrease of 11.44% [1] Group 2 - On August 4, 2025, the net outflow of main funds was 8.6364 million yuan, with a cumulative net outflow of 46.7694 million yuan over the past five trading days [1] - The company's total share capital is 79.0048 million shares, with 75.3189 million shares in circulation, and the average holding of circulating shares per shareholder is 8,623 shares, with an average circulating market value of 352,800 yuan [1]

证券日报网讯 7月31日晚间，普蕊斯发布公告称，公司分别于2025年4月25日、2025年5月20日召开公司 第三届董事会第十二次会议、2024年年度股东大会，审议通过了《关于回购注销2022年限制性股票激励 计划部分限制性股票的议案》《关于变更公司注册资本、修订并办理工商变更登记及备案的议案》。公 司于2025年7月23日在中国证券登记结算有限责任公司深圳分公司完成回购、注销手续。公司总股本由 79，502，540股变更为79，004，770股，公司注册资本由人民币79，502，540元变更为人民币79， 004，770元。近日，经上海市市场监督管理局核准，公司已完成相关工商变更登记及《公司章程》备案 手续，并取得了换发的《营业执照》。 （文章来源：证券日报） ...

证券代码：301257 证券简称：普蕊斯 公告编号：2025-045 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）分别于 2025 年 4 月 25 日、2025 年 5 月 20 日召开公司第三届董事会第十二次会议、2024 年 年度股东大会，审议通过了《关于回购注销 2022 年限制性股票激励计划部分限 制性股票的议案》《关于变更公司注册资本、修订<公司章程>并办理工商变更登 记及备案的议案》。具体内容详见公司于 2025 年 4 月 29 日在巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于回购注销 2022 年限制性股票激励计划 部分限制性股票及调整回购价格的公告》《关于变更公司注册资本、修订<公司 章程>并办理工商变更登记及备案的公告》。 公司于 2025 年 7 月 23 日在中国证券登记结算有限责任公司深圳分公司完 成回购、注销手续。公司总股本由 79,502,540 股变更为 79,004,770 股，公司注册 资本由人民币 79,502,540 元变更为 ...

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [5] Core Insights - The 2025 World Artificial Intelligence Conference (WAIC) showcased significant advancements in AI technology, particularly in computing power, algorithms, and applications, indicating a robust growth trajectory for the industry [12][60] - Domestic manufacturers are progressively enhancing their chip performance from inference to training, emphasizing ecosystem support and application scenarios [13][60] - The report highlights the emergence of quantum computing as a disruptive innovation in the computing power industry, with potential for exponential growth in computational capabilities [38][39] Summary by Sections 1. Industry Overview - The WAIC 2025 featured over 800 companies and more than 3000 cutting-edge exhibits, marking the largest scale in its history [12] - The conference focused on AI technology frontiers, industry trends, and global governance practices [12] 2. Computing Power - Domestic chip manufacturers are evolving from inference-focused AI chips to high-performance training chips, showcasing various industry applications [13] - The report notes the importance of supernodes, integrated machines, and liquid cooling solutions as key trends in the future of domestic AI computing power [18][19] 3. Algorithms - The evolution of large models is highlighted, with a shift towards multi-modal capabilities and the integration of deep reasoning and thinking abilities [43][44] - The report emphasizes the growing importance of AI agents and physical AI, which aim to enable intelligent agents to understand and interact with the real world [43][44] 4. Applications - The report identifies a flourishing landscape for both B2B and B2C AI applications, with significant advancements in areas such as AI glasses, smart driving, and robotics [60] - C-end applications focus on AIGC and productivity tools, while B-end applications emphasize cost reduction and efficiency improvements across various sectors [60][61] 5. Quantum Computing - Quantum computing is positioned as a critical future technology, with companies showcasing solutions that leverage quantum mechanics for superior computational capabilities [38][39]

证券代码:301257 证券简称:普蕊斯 公告编号:2025-044 普蕊斯（上海）医药科技开发股份有限公司 关于 2022 年限制性股票激励计划 1、普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）本次回 购注销的限制性股票数量为 49.777 万股，占回购前公司总股本的 0.63%。本次注 销完成后，公司总股本由 79,502,540 股减至 79,004,770 股。 2、本次回购注销涉及人数为 135 人，回购价格为 12.61 元/股。 3、本次回购总金额为 6,276,879.70 元，回购资金为公司自有资金。 4、公司于 2025 年 7 月 23 日在中国证券登记结算有限责任公司深圳分公司 完成回购、注销手续。 一、2022 年限制性股票激励计划已履行的相关审批程序 （一）2022 年 9 月 5 日，公司召开第二届董事会第十九次会议，会议审议 通过了《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关 于公司<2022 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提 请公司股东大会授权董事会办理 2022 年限制性股票激励计划相关事宜的议案》， 公司 ...

Financial Performance - In 2024, the company achieved operating revenue of 803.73 million yuan, a year-on-year increase of 5.75% [2] - The net profit attributable to shareholders was 106.43 million yuan, a decrease of 21.01% year-on-year [2] - The net profit excluding non-recurring gains and losses was 83.47 million yuan, down 26.88% year-on-year, primarily due to increased operating costs from hiring new staff [2] - In Q1 2025, operating revenue was 176.47 million yuan, a decline of 4.37% year-on-year [2] - The net profit attributable to shareholders in Q1 2025 was 7.43 million yuan, a decrease of 67.32% year-on-year [2] Contractual and Project Management - The company signed new contracts worth 1 billion yuan, with a total outstanding contract amount of 1.889 billion yuan by the end of 2024, reflecting a year-on-year growth of 0.38% [2] - As of March 31, 2025, the company had undertaken over 3,800 international and domestic SMO projects, with 2,250 projects currently in execution [2] - The company has a total workforce of 4,277 employees and serves over 960 clinical trial institutions across more than 200 cities in China [2] Shareholder Value and Dividends - The total cash dividend for the first half and full year of 2024 was 19.88 million yuan, accounting for 18.68% of the net profit for 2024 [2] - Cumulatively, from 2022 to 2024, the company distributed a total of 40.77 million yuan in cash dividends [2] Industry Insights and Future Outlook - The SMO industry is entering a new development phase, with leading companies expanding client resources and institutional coverage, while smaller firms are gradually exiting the market [3] - In 2024, Chinese pharmaceutical companies achieved a historic breakthrough in licensing-out transactions, totaling 51.9 billion USD, with 4.1 billion USD in upfront payments [3] - The company plans to continue innovating in organizational management and explore the application of AI and new technologies in clinical trial execution [3] Competitive Advantages - The company has strong competitive advantages in various disease areas, including hematological tumors, solid tumors, and rare diseases, having facilitated the launch of 82 new oncology drugs and 14 biosimilars by the end of 2024 [4] - As of December 2024, the company participated in 10 projects related to therapeutic nuclear drugs, 87 TCR projects, 67 ADC projects, and 24 CGT projects [4] - Notable products launched include the world's first approved CLDN18.2 targeted therapy and the first approved oral GLP-1 drug in China [4]

Core Points - The legal opinion letter confirms the legality of the convening and voting procedures of the second extraordinary general meeting of shareholders of Proris (Shanghai) Pharmaceutical Technology Development Co., Ltd. in 2025 [2][6] - The meeting was convened by the board of directors and held on July 21, 2025, with a combination of on-site and online voting [3][5] - The total number of shareholders present at the meeting was 126, representing 41,496,106 shares, which accounted for 52.1947% of the total shares [5] Meeting Procedures - The meeting was called by the board of directors and the notice was published on the Shenzhen Stock Exchange and other platforms on July 5, 2025 [3][5] - The meeting was held at the World Trade Center in Shanghai and was presided over by the chairman of Proris, Lai Chunbao [3][5] - Voting was conducted through both on-site and online methods, with specific time slots allocated for online voting [3][5] Voting Results - The first resolution regarding participation in the auction and establishment of real estate equity and corresponding debt was approved with 41,400,571 votes in favor, representing 99.7698% of the votes [6] - The second resolution concerning financial assistance to a proposed equity investment company was also approved with 41,374,691 votes in favor, representing 99.7074% of the votes [6] - The voting process was monitored and verified, ensuring compliance with legal and regulatory requirements [6]

1、本次会议采取现场表决与网络投票相结合的方式。 证券代码：301257 证券简称：普蕊斯 公告编号：2025-043 普蕊斯（上海）医药科技开发股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 2、召开地点：上海市黄浦区广东路 500 号世界贸易大厦 23 楼大会议室 3、召开方式：现场表决与网络投票相结合的方式 4、召集人：普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"或 "普蕊斯"）董事会 5、主持人：董事长赖春宝先生 6、本次会议的召集、召开符合《公司法》《上市公司股东大会规则》（以 下简称"《股东大会规则》"）《深圳证券交易所创业板股票上市规则》等有关 法律、行政法规、部门规章、规范性文件和《公司章程》的有关规定。 （2）网络投票时间：通过深交所交易系统进行网络投票的具体时间为：2025 年 7 月 21 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深交所互联网投票系统 投票的具体时间为 2025 年 7 月 21 日 9:15-15:00 期 ...